Large-cell Lymphoma
8
1
3
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
12.5%
1 terminated out of 8 trials
66.7%
-19.8% vs benchmark
0%
0 trials in Phase 3/4
150%
3 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (8)
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma
Telehealth-based Symptom Management for Veterans Treated With Selinexor
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies